Changes in the gut microbiota may underpin many human diseases, but the mechanisms that are responsible for altering microbial communities remain poorly understood. Antibiotic usage elevates the risk of contracting gastroenteritis caused by Salmonella enterica serovars 1 , increases the duration for which patients shed the pathogen in their faeces, and may on occasion produce a bacteriologic and symptomatic relapse 2,3 . These antibiotic-induced changes in the gut microbiota can be studied in mice, in which the disruption of a balanced microbial community by treatment with the antibiotic streptomycin leads to an expansion of S. enterica serovars in the large bowel 4 . However, the mechanisms by which streptomycin treatment drives an expansion of S. enterica serovars are not fully resolved. Here we show that host-mediated oxidation of galactose and glucose promotes post-antibiotic expansion of S. enterica serovar Typhimurium (S. Typhimurium). By elevating expression of the gene encoding inducible nitric oxide synthase (iNOS) in the caecal mucosa, streptomycin treatment increased post-antibiotic availability of the oxidation products galactarate and glucarate in the murine caecum. S. Typhimurium used galactarate and glucarate within the gut lumen of streptomycin pre-treated mice, and genetic ablation of the respective catabolic pathways reduced S. Typhimurium competitiveness. Our results identify host-mediated oxidation of carbohydrates in the gut as a mechanism for post-antibiotic pathogen expansion.
galactarate/glucarate utilization genes did not reduce the fitness of S. Typhimurium for anaerobic growth on hog mucin as the sole carbon source, but fitness of the gudT-STM2959 mutant was reduced compared to the wild type when galactarate or glucarate was added to the medium (Fig. 1b) . These data suggested that neither the diet nor the mucus naturally contained biologically relevant quantities of a substrate for enzymes encoded by the gudT ygcY gudD STM2959 operon.
We next investigated the contribution of the gudT ygcY gudD STM2959 operon to post-antibiotic pathogen expansion. Treatment of mice with a single dose of streptomycin one day before infection (pre-treatment with streptomycin) increased recovery of the wild-type S. Typhimurium from the colon contents of mice by approximately one order of magnitude compared to animals that had not received antibiotics (P < 0.05) ( Fig. 1c ). Genetic ablation of the galactarate/ glucarate utilization genes significantly (P < 0.05) reduced recovery of S. Typhimurium from streptomycin pre-treated mice, but not from mice that had not received antibiotics. Genetic complementation with a plasmid carrying the cloned gudT ygcY gudD STM2959 genes restored recovery of the gudT-STM2959 mutant from streptomycin pre-treated mice to levels observed with the wild-type S. Typhimurium. Collectively, these data provided genetic evidence for a contribution of the gudT ygcY gudD STM2959 operon to post-antibiotic expansion of S. Typhimurium.
Preconditioning of mice with streptomycin increases the severity of S. Typhimurium induced colitis 9 . We therefore investigated whether the availability of galactarate and/or glucarate is elevated during severe colitis, a host response triggered by the action of two type III secretion systems (T3SS-1 and T3SS-2), which constitute the main virulence factors of S. Typhimurium 9, 10 . To prevent the generation of acute intestinal inflammation, we used avirulent S. Typhimurium strains lacking a functional T3SS-1 (due to a mutation in invA) and T3SS-2 (due to a mutation in spiB). Streptomycin pre-treated mice were infected either with a 1:1 mixture of the wild-type bacteria and a gudT-STM2959 mutant or with a 1:1 mixture of an invA spiB mutant and an invA spiB gudT-STM2959 mutant. In each competition, the galactarate/glucarate utilization-proficient strain (the wild-type bacteria or the invA spiB mutant) was recovered in higher numbers than the corresponding galactarate/glucarate utilization-deficient strain (the gudT-STM2959 mutant or the invA spiB gudT-STM2959 mutant) ( Fig. 2a ). However, only mice infected with a mixture of the wild-type bacteria and a gudT-STM2959 mutant developed acute intestinal inflammation (Extended Data Fig. 2 and Extended Data Tables 1 and 2 ). When the experiment was repeated with mice that had not received streptomycin, the presence of genes for galactarate/glucarate utilization no longer conferred a fitness advantage ( Fig. 2a ). To distinguish between glucarate and galactarate as possible carbon sources, we inactivated gudD, encoding glucarate dehydratase, or garD, encoding galactarate dehydratase (Extended Data Fig. 1c ). During in vitro growth, genetic ablation of gudD only reduced S. Typhimurium fitness in medium containing glucarate, while deletion of the garD gene only reduced fitness in Letter reSeArCH 6 9 8 | n A T u R e | V O L 5 3 4 | 3 0 j u n e 2 0 1 6 medium containing galactarate (Extended Data Fig. 1d ). Both the garD gene and the gudD gene conferred a fitness advantage in streptomycin pre-treated mice (Extended Data Fig. 1e ). Collectively, these data suggested that streptomycin treatment increased the availability of both glucarate and galactarate through a mechanism that was streptomycin-dependent, but independent of acute colitis triggered by S. Typhimurium virulence factors.
Antibiotic treatment increases the availability of sialic acid and fucose in the large intestine. It has been proposed that these monosaccharides are liberated by the resident microbiota from complex carbohydrates, a conclusion based on the observation that sialic acid and fucose are absent from caecal contents of germ-free mice 11 . We thus investigated the possibility that the gut microbiota might play a role in liberating galactarate from complex carbohydrates in the intestine. Conventional mice (non-germ-free with a normal microbiota) received either streptomycin or vehicle control by oral gavage and the concentrations of galactarate and glucarate were measured in caecal contents by GC/MS four days later (Extended Data Fig. 3a, b ). The concentration of galactarate was low in mice that had not received antibiotics, and streptomycin treatment resulted in a marked increase in the amount of galactarate present in the caecum (P < 0.001) ( Fig. 2b) . Similarly, streptomycin treatment increased (P < 0.001) caecal glucarate concentrations ( Fig. 2c ). We reasoned that if galactarate and glucarate present in streptomycin-treated mice was microbiota-liberated, then the concentrations of these sugars should be markedly reduced or absent in germfree animals. Surprisingly, galactarate and glucarate levels measured by GC/MS in caecal contents of germ-free mice were similar or higher than those detected in conventional mice pre-treated with streptomycin ( Fig. 2b, c) . These data ruled out microbiota liberation as a possible mechanism by which streptomycin treatment elevated the availability of galactarate and glucarate in the murine large intestine.
Streptomycin treatment of mice induces elevated caecal mucosal transcript levels of Nos2, the gene encoding inducible nitric oxide synthase (iNOS), through an unknown mechanism 12 (Extended Data Fig. 4a ). To determine whether the luminal fitness advantage conferred by galactarate/glucarate utilization genes required Nos2 expression, streptomycin pre-treated Nos2-deficient mice were infected either with a 1:1 mixture of the wild-type S. Typhimurium and a gudT-STM2959 mutant or with a 1:1 mixture of an invA spiB mutant and an invA spiB gudT-STM2959 mutant. Remarkably, in each experiment, the luminal fitness advantage conferred by the galactarate/glucarate utilization genes after streptomycin treatment was abrogated in Nos2-deficient mice ( Fig. 2a ). These data suggested that the Nos2 gene was necessary to generate a substrate for enzymes encoded by the gudT ygcY gudD STM2959 operon.
To determine whether the streptomycin-induced increase in the caecal galactarate and glucarate concentrations (Fig. 2b, c) was Nos2dependent, we measured galactarate and glucarate concentrations in caecal contents from Nos2-deficient mice four days after streptomycin treatment by GC/MS. Strikingly, streptomycin treatment did not increase the availability of these sugars in Nos2-deficient mice (Fig. 2b, c) . These data further supported the idea that generation of post-antibiotic galactarate and glucarate required an intact Nos2 gene.
To investigate whether the fitness advantage conferred by galactarate/ glucarate utilization required iNOS activity, streptomycin-treated mice (C57BL/6) received drinking water supplemented with aminoguanidine hydrochloride, a specific iNOS inhibitor 13 , and were infected with a 1:1 mixture of the wild-type S. Typhimurium and a gudT-STM2959 mutant. Inhibition of iNOS activity with AG significantly (P < 0.05) blunted the fitness advantage conferred by the galactarate/glucarate utilization genes ( Fig. 2a ), suggesting that iNOS activity was required for generating galactarate and glucarate in the large intestine.
The host enzyme iNOS uses l-arginine to produce nitric oxide (NO), a reactive nitrogen species 14 . Reactive nitrogen species are known catalysts in the oxidation of alcohols and aldehydes 15 . We thus hypothesized that by generating reactive nitrogen species, streptomycin-induced iNOS synthesis might drive an oxidation of monosaccharides, thereby yielding the oxidation products galactarate and glucarate. To investigate whether reactive nitrogen species might oxidize galactose and glucose to galactarate and glucarate, respectively, we used 2,2,6,6-tetramethyl piperidine-1-oxyl (TEMPO), which is a stable free nitrosyl radical that mimics the activity of reactive nitrogen species (reviewed in ref. 16 ). Galactose and glucose were incubated in the presence of TEMPO and a co-oxidant (NaOCl) or the co-oxidant alone. Detection by GC/MS indicated that TEMPO oxidized galactose to galactarate ( Fig. 2d ) and glucose to glucarate ( Fig. 2e ). Next, we investigated whether the monosaccharides galactose and glucose were present in caecal contents. Galactose and glucose were detected in caecal contents of conventional (C57BL/6) mice, Nos2-deficient mice and germ-free mice (Fig. 2f, g) . Collectively, these data suggested that monosaccharides were present in the murine caecum and could be oxidized by reactive nitrogen species to yield galactarate and glucarate.
Gene clusters for the utilization of galactarate and glucarate are also present in Escherichia coli and other related Enterobacteriaceae (Extended Data Fig. 1c ). As treatment with streptomycin leads to an uncontrolled expansion of E. coli in the murine intestine 17 , we investigated whether the underlying mechanism also involved utilization of galactarate and glucarate. To test this, we deleted the gudDXP and garD genes in the human E. coli isolate Nissle 1917 (Extended Data Fig. 1c ). Deletion of the gudDXP garD genes rendered E. coli unable to grow with galactarate or glucarate as the sole carbon source, but did not affect its ability to utilize glycerate (Extended Data Fig. 5a ). The gudDXP garD genes conferred a fitness advantage during growth of E. coli in the colon of streptomycin pre-treated mice, which was significantly (P < 0.05) diminished after treatment with the iNOS inhibitor aminoguanidine hydrochloride (Extended Data Fig. 5b ).
Here we show that by inducing the production of host-derived reactive nitrogen species, streptomycin treatment generates galactarate and glucarate in the gut lumen, thereby providing S. Typhimurium and E. coli with a considerable fitness advantage. Increases in galactarate and glucarate levels are also observed after treatment of mice with cefoperazone or a cocktail of vancomycin and bacitracin 18, 19 . A post-antibiotic expansion of Enterobacteriaceae is of concern due to the recent emergence of carbapenem antibiotic resistance within this group. Exposure of patients in intensive care units to broad-spectrum antibiotics is a known risk factor for acquiring an infection with carbapenem-resistant E. coli and Klebsiella isolates 20 . Our findings identify host-mediated sugar oxidation as a new mechanism contributing to post-antibiotic expansion of Enterobacteriaceae.
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MethOdS Bacterial strains and growth conditions. S. Typhimurium and E. coli strains used in this study are listed in Extended Data Table 3 . All cultures were routinely grown aerobically at 37 °C in either Luria-Bertani (LB) broth (10 g per litre tryptone, 5 g per litre yeast extract, 10 g per litre NaCl) or on LB agar plates (1.5% Difco agar) unless indicated otherwise. When necessary, antibiotics were added to the medium at the following concentrations: nalidixic acid (Nal) 50 mg per litre, kanamycin (Km) 100 mg per litre, chloramphenicol (Cm) 30 mg per litre, carbenicillin (Carb) 100 mg per litre. Sugar fermentation assay. 5 ml of fermentation broth (peptone, 10 g per litre; bromothymol blue, 0.024 g per litre; final pH 7.4 ± 0.1) supplemented with the indicated carbon source (galactarate, glucarate, glucose, galactose, mannose or rhamnose, 10 g per litre each) or the control broth (no sugar added) were inoculated with 10 μ l of an overnight culture of each indicated S. Typhimurium strain and incubated statically at 37 °C for 24 h. Fermentation of the sugar in the broth is indicated by a colour change from blue to yellow. Anaerobic growth assays. 10 ml of M9 minimal medium (75 g per litre Na 2 HPO 4 x2H 2 O, 30 g per litre KH 2 PO 4 , 5 g per litre NaCl, 10 g per litre NH 4 Cl, 0.1 mM CaCl 2 , 1 mM MgSO 4 , 0.001% thiamine) supplemented with hog mucin (0.1% w/v) or galactarate (0.04% w/v when added as sole carbon source, 0.1% w/v and 0.01% w/v when added to mucin broth) were inoculated with 2 × 10 3 colony-forming units (CFU) of each strain and incubated anaerobically at 37 °C for 24 h inside an anaerobic chamber (Bactron I Anerobic Chamber; Sheldon Manufacturing, Cornelius). Bacterial numbers were determined by plating serial tenfold dilutions onto LB agar containing the appropriate antibiotics. The ratios of recovered wild-type and mutant bacteria after 24 h were normalized to the ratio at 0 h to calculate the competitive index. Construction of plasmids. Standard cloning techniques were used to generate the plasmids used in this study. All plasmids and primers used in this study are listed in Extended Data Tables 4 and 5 . PCR products were confirmed by sequencing (SeqWright Fisher Scientific, Houston). Suicide plasmids were propagated in E. coli DH5a λ pir. Plasmid pFF35 was constructed by PCR amplifying a 5′ flanking fragment of gudT using primers 71 and 72 and a 3′ flanking fragment STM2959 using primers 73 and 74. The two PCR fragments were gel purified, digested with XbaI and ligated with T4 DNA ligase (NEB). The ligation mix served as a template for a PCR with primers 71 and 74 and the product was gel purified and cloned into pCR2.1 using the TOPO TA cloning kit (Invitrogen). The plasmid construct was confirmed by sequencing and designated pFF35. To generate a suicide plasmid for replacing the gudT ygcY gudD STM2959 genes with a kanamycin (KSAC) cassette, the insert of plasmid pFF35 was excised using BamHI and ligated into the BamHI site of the suicide plasmid pRDH10. The resulting plasmid was digested with XbaI and ligated with a KSAC cassette generated from pBS34 by digestion with XbaI. The resulting suicide plasmid was designated pFF57.
To construct plasmids pFF62 and pFF63, respectively, chromosomal regions upstream and downstream of gudD and garD in IR715 were amplified by PCR and cloned into BamHI-digested pRDH10 using Gibson Assembly Master Mix (NEB). To construct plasmids pFF64 and pFF65, respectively, chromosomal regions upstream and downstream of the gudDXP operon and of garD from E. coli Nissle 1917 were amplified by PCR and cloned into BamHI digested pRDH10 using Gibson Assembly Master Mix (NEB).
For complementation of the gudT-STM2959 mutant, the gudT ygcY gudD STM2959 operon including its promoter region was PCR amplified using primers 92 and 93 or 94 and 95. The two PCR fragments were gel purified and cloned into BamHI digested pWSK29 using Gibson Assembly Master Mix (NEB). The complementation plasmid was verified by sequencing and designated pGUDT. Construction of mutants in S. Typhimurium. All suicide plasmids were introduced into S. Typhimurium IR715 recipient strains by conjugation using E. coli S17-1λ pir as the donor strain. Exconjugants were selected on LB + Nal + Cm to select for clones that had integrated the suicide plasmid. Sucrose counter-selection was performed as published previously 21 . Strains that were sucrose resistant and Cm S were verified by PCR.
Plasmid pFF57 was introduced into FF7 and SPN487 to generate FF162 (Δ gudT-STM2959::Km R ) and FF217 (Δ invA Δ spiB Δ gudT-STM2959::Km R ), respectively. Plasmid pFF62 was introduced into AJB715 to generate FF464 (phoN::Km R Δ invA Δ spiB gudD). Plasmid pFF63 was introduced into AJB715 to generate strain FF461 (phoN::Km R Δ invA Δ spiB garD). Construction of mutants in E. coli Nissle 1917. Suicide plasmids were introduced into E. coli Nissle 1917(pSW172) recipient strains by conjugation using E. coli S17-1λ pir as the donor strain. To ensure stable propagation of pSW172, all steps of the conjugation were performed at 30 °C. Exconjugants were selected on LB + Carb + Cm to select for clones that had integrated the suicide plasmid. Subsequent sucrose counter-selection was performed as published previously 21 . Strains that were sucrose resistant and Cm S were verified by PCR. If appropriate, pSW172 was cured by growing the resulting mutant strains at 37 °C. Plasmids pFF64 and pFF65 were successively introduced into E. coli Nissle 1917(pSW172) to generate FF441 (E. coli Nissle 1917 gudDXP garD). Generalized phage transduction. Phage P22 HT105/1 int-201 was used for generalized transduction. A phage lysate of strain CS019 was used to transduce IR715 wild-type and the Δ invA Δ spiB mutant (SPN487) to Cm R generating FF176 (IR715 phoN::Tn10d-Cam) and FF183 (IR715 phoN::Tn10d-Cam Δ invA Δ spiB), respectively. Transductants were cleaned from phage contaminations on Evans blue-Uranine (EBU) agar plates and tested for phage sensitivity by cross-streaking against P22 H5. The strains were verified by PCR to be phoN::Tn10d-Cam. Animal experiments. No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were blinded to allocation of mice for assessment of histopathology and readouts of inflammation. All animal experiments were approved by the Institutional Animal Care and Use Committees at the University of California, Davis. Female C57BL/6J wild-type and Nos2-deficient mice (B6.129P2-Nos2 tm1Lau /J) aged 9-12 weeks were obtained from The Jackson Laboratory (Bar Harbour). Mice were pre-treated with an oral dose of 20 mg streptomycin or sterile water 24 h before infection with S. Typhimurium or E. coli Nissle 1917, respectively. For single infections with Salmonella, mice were inoculated intra-gastrically with 2 × 10 8 CFU of the indicated S. Typhimurium strains. For competitive infections, mice were inoculated with a 1:1 mixture of each indicated strain. For infection with E. coli Nissle 1917, mice were infected with 2 × 10 9 CFU of a 1:1 mixture of the indicated strains. In some experiments, drinking water was supplemented with aminoguanidine hydrochloride (1 mg ml −1 ). Mice were euthanized 4 days after infection. The colon contents were collected for enumeration of bacterial numbers, the distal caecum was collected for histopathology scoring. Bacterial numbers were determined by plating serial tenfold dilutions onto LB agar containing the appropriate antibiotics. The ratio of recovered wild-type and mutant bacteria in colon contents were normalized by the ratio in the inoculum to calculate the competitive index. For measurements of sugar concentrations in caecal contents, mice received an oral dose of either 20mg streptomycin or sterile water. Mice were euthanized 4 days after streptomycin treatment and caecal contents were snap frozen in liquid nitrogen and stored at − 80 °C. The distal caecal tissue was collected for RNA isolation.
Germ-free Swiss Webster mice were obtained from Taconic Farms. The mice were bred and housed under germ-free conditions inside gnotobiotic isolators (Park Bioservices, LLC). Weekly 16 S PCR and cultures were performed to evaluate the germ-free status of the mice. For experiments, male and female 6-8-week-old mice were transferred to a biosafety cabinet and maintained in sterile cages for the duration of the experiment. Caecal contents were snap frozen in liquid nitrogen and stored at − 80 °C until further processing for metabolite measurements. Quantitative real-time RT-PCR analysis. Murine caecal tissue was collected, snap frozen in liquid nitrogen and stored at − 80 °C. Expression analysis was performed as described previously 22 . Briefly, RNA was extracted using TRI reagent (Molecular Research Center, Cincinnati) according to the manufacturer's protocol. Isolated RNA was DNase-treated (Applied Biosystems) and cDNA was synthesized from 1 μ g of RNA using TaqMan reverse transcription reagents (Applied Biosystems). Real-time PCR was performed using SYBR-Green (Applied Biosystems) and the primers listed in Extended Data Table 5 . The changes in mRNA levels of target genes were calculated using the comparative Ct method (Applied Biosystems) and normalized to the levels of B2m mRNA. Histopathology. The distal caecal tissue was fixed in phosphate-buffered formalin and 5 μ m sections of the tissue were stained with haematoxylin and eosin. Blinded scoring of tissue sections was performed by a veterinary pathologist based on the criteria listed in Extended Data Tables 1 and 2 . Images were taken with a Zeiss Primo Star microscope with a 10× objective. TEMPO-mediated oxidation of sugars. The oxidation reactions were carried out at room temperature in an open beaker fitted with a pH-meter electrode and a thermometer to monitor the reactions. The pH was kept constant at 8 by titration with a 0.5 M NaOH solution. d-galactose (2 g) and TEMPO (16 mg, 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical, Sigma-Aldrich) were dissolved in 250 ml ultrapure water. As a control some of the oxidations were done without adding TEMPO to the reaction mixture. To start the oxidation, sodium hypochlorite solution (a total of 11 ml of 10-15% NaClO, Sigma-Aldrich) was added at a rate not exceeding a pH of 8.0. After adding the entire NaClO solution the pH was kept at 8.0 until no further pH shift was detectable. The reaction mixture was precipitated with 3 volumes of ≥ 95% ethanol at 4 °C for 48 h, filtered (Whatman qualitative filter paper, grade 602 h), washed with acetone and dried at 50 °C for 10-15 h. The resulting powdered mixture was used as a carbon source for in vitro growth assays and analysed by GC/MS for the presence of galactarate. 

